This company has been acquired

The company may no longer be operating, as it has been acquired. Find out why through their latest events.
We’ve recently updated our valuation analysis.

Abiomed Valuation

Is ABMD undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

0/6

Valuation Score 0/6

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Below Fair Value

  • Significantly Below Fair Value

  • Analyst Forecast

Key Valuation Metric

Which metric is best to use when looking at relative valuation for ABMD?

Other financial metrics that can be useful for relative valuation.

ABMD key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue15.1x
Enterprise Value/EBITDA59.3x
PEG Ratio-26x

Price to Earnings Ratio vs Peers

How does ABMD's PE Ratio compare to its peers?

The above table shows the PE ratio for ABMD vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyPEEstimated GrowthMarket Cap
Peer Average41x
HOLX Hologic
21.1x6.1%US$20.9b
TFX Teleflex
29.4x11.3%US$12.1b
RMD ResMed
40.8x12.7%US$33.0b
ZBH Zimmer Biomet Holdings
84.2x21.2%US$27.2b
ABMD Abiomed
64.4x-2.5%US$17.2b

Price-To-Earnings vs Peers: ABMD is expensive based on its Price-To-Earnings Ratio (64.4x) compared to the peer average (41x).


Price to Earnings Ratio vs Industry

How does ABMD's PE Ratio compare vs other companies in the US Medical Equipment Industry?

0 CompaniesPrice / EarningsEstimated GrowthMarket Cap
Industry Avg.n/a17.5%
n/an/an/a

Price-To-Earnings vs Industry: ABMD is expensive based on its Price-To-Earnings Ratio (64.4x) compared to the US Medical Equipment industry average (31.9x)


Price to Earnings Ratio vs Fair Ratio

What is ABMD's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

ABMD PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio64.4x
Fair PE Ratio26.9x

Price-To-Earnings vs Fair Ratio: ABMD is expensive based on its Price-To-Earnings Ratio (64.4x) compared to the estimated Fair Price-To-Earnings Ratio (26.9x).


Share Price vs Fair Value

What is the Fair Price of ABMD when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: ABMD ($381.02) is trading above our estimate of fair value ($72.57)

Significantly Below Fair Value: ABMD is trading above our estimate of fair value.


Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst ABMD forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
Currentn/a
US$353.33
0%
10.7%US$380.00US$300.00n/a3
Jan ’24n/a
US$353.33
0%
10.7%US$380.00US$300.00n/a3
Dec ’23US$377.44
US$362.00
-4.1%
9.9%US$388.00US$300.00n/a4
Nov ’23US$377.82
US$317.50
-16.0%
17.6%US$380.00US$235.00n/a4
Oct ’23US$245.66
US$338.33
+37.7%
23.2%US$425.00US$235.00n/a3
Sep ’23US$259.53
US$351.25
+35.3%
20.4%US$425.00US$235.00n/a4
Aug ’23US$291.90
US$333.00
+14.1%
22.1%US$425.00US$235.00n/a5
Jul ’23US$254.56
US$352.00
+38.3%
19.9%US$425.00US$260.00n/a5
Jun ’23US$255.36
US$347.50
+36.1%
18.6%US$425.00US$260.00n/a6
May ’23US$286.58
US$354.17
+23.6%
16.1%US$425.00US$275.00n/a6
Apr ’23US$338.64
US$365.00
+7.8%
15.5%US$425.00US$275.00n/a5
Mar ’23US$313.49
US$365.00
+16.4%
15.5%US$425.00US$275.00n/a5
Feb ’23US$301.35
US$372.40
+23.6%
13.0%US$425.00US$292.00n/a5
Jan ’23US$359.17
US$379.80
+5.7%
15.3%US$425.00US$269.00n/a5
Dec ’22US$305.71
US$387.33
+26.7%
14.4%US$425.00US$269.00US$377.446
Nov ’22US$349.99
US$387.33
+10.7%
14.4%US$425.00US$269.00US$377.826
Oct ’22US$323.33
US$387.33
+19.8%
14.4%US$425.00US$269.00US$245.666
Sep ’22US$363.27
US$387.33
+6.6%
14.4%US$425.00US$269.00US$259.536
Aug ’22US$327.14
US$368.33
+12.6%
17.7%US$425.00US$245.00US$291.906
Jul ’22US$312.91
US$371.67
+18.8%
17.2%US$425.00US$245.00US$254.566
Jun ’22US$279.70
US$374.00
+33.7%
18.6%US$425.00US$245.00US$255.365
May ’22US$320.73
US$374.00
+16.6%
18.6%US$425.00US$245.00US$286.585
Apr ’22US$315.34
US$366.25
+16.1%
19.8%US$425.00US$245.00US$338.644
Mar ’22US$324.26
US$378.00
+16.6%
18.3%US$425.00US$245.00US$313.495
Feb ’22US$341.86
US$378.00
+10.6%
18.3%US$425.00US$245.00US$301.355

Analyst Forecast: Target price is lower than the current share price.


Discover undervalued companies